Analysts expect Bone Biologics Corp to report revenue of 0.00 for Q3 24, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 26, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - |
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Bone Biologics Corp to report earnings per share of -3.51 for Q3 24, against a range of -3.77 to -3.25. The most recent reported quarter, Q1 26, came in at -0.43, a 6.5% beat against the -0.46 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | -0.32 | -1.33 | -0.37 | -0.58 | -0.43 | - | - | - | - | - | - | |||||
| High Estimate | -3.25 | -3.42 | -3.05 | -0.57 | -0.34 | -0.32 | -0.44 | -0.43 | -0.17 | -0.17 | -0.12 | -0.53 | 0.02 | |||||
| Low Estimate | -3.77 | -3.94 | -3.65 | -0.63 | -0.36 | -0.38 | -0.48 | -0.47 | -0.19 | -0.19 | -0.14 | -0.57 | 0.02 | |||||
| Consensus Estimate | -3.51 | -3.68 | -3.35 | -0.60 | -0.35 | -0.35 | -0.46 | -0.45 | -0.18 | -0.18 | -0.13 | -0.55 | 0.02 |